Introduction
It has been shown (Tumer-Warwick and Doniach, 1965) that there is an increased prevalence of antinuclear and rheumatoid factors in patients with the clinical syndrome of cryptogenic fibrosing alveolitis (idiopathic diffuse interstitial pulmonary fibrosis). Similarity between this syndrome and the clinical and pathological features seen in asbestosis suggested the possibility of circulating autoantibodies being found in persons with asbestosis. Pernis and Vigliani (1965) have reported an increased prevalence of rheumatoid factor in asbestos workers, especially those with abnormal chest radiographs; the overlap between asbestosis and "rheumatoid" diseases is further suggested by the rare occurrence of necrobiotic nodules in the lungs in asbestos workers (Rickards and Barrett, 1958; Tellesson, 1961; Morgan, 1964) . We know of no published reports of circulating antinuclear factors in asbestosis. Studies of other pneumoconioses, especially that due to inhalation of coal dust, have already shown an association between certain radiographic features and the presence of both clinical rheumatoid arthritis and circulating rheumatoid factor (Caplan, 1953; Caplan et al., 1962; Lindars and Davies, 1967 More severe radiographic shadowing is related significantly to the presence of antibodies (Table III) , and this is reflected in an analysis of both the profusion and the coarseness of radiographic shadows. Nevertheless, coarse and extensive radiographic shadows were seen in some patients without circulating antibodies, and honeycombing was seen with equal frequency in both groups. disease, while of 13 without tissue antibodies only four showed evidence of radiographic progression.
Discussion
The prevalence of both antinuclear and rheumatoid factors in this series is at least four times greater than has been found in random populations of this age group. Antinuclear factors in titres of 1: 10 and over has been found in about 5 % of subjects in a large number of control groups which included men and women: and titres of 1: 16 and over in men over 40 years old in less than 2% (Beck, 1963) . Rheumatoid factors have also been found in about 5% of random populations of men and women (Ball and Lawrence, 1961) , in comparison with the incidence of our series of 27%. The titres of antinuclear factors observed in our cases were lower than those in typical systemic lupus erythematosus, where titres are often in excess of 1: 200; but they do show a distribution similar to the titres in cryptogenic fibrosing alveolitis, where titres of 1:50 and over were found in 30% of positive sera (Turner-Warwick, unpublished) .
Antinuclear factor found in "autoimmune" disease may belong to various immunoglobulin classes, and A.N.F. activity can often be identified in more than one Ig class within the same serum (Barnett et al., 1965 (Holborow and Johnson, 1965) . In common with these connective-tissue disorders our asbestosis sera showed a predominantly IgM type of A.N.F.
The presence of rheumatoid factor in our series confirms the finings of Pernis and Vigliani (1965) and shows that the small irregular type of radiographic appearances in asbestosis can be associated with circulating antiglobulin factors of similar types as have been described in association with the nodular appearance seen in the pneumocomosis of coal miners (Caplan et al., 1962) . A range of lung changes associated with circulating rheumatoid factor is now beginning to emerge. In patients with seropositive rheumatoid arthritis without industrial dust exposure, two types of pathological change are seen in the lung-namely, diffuse interstitial fibrosis (radiographically characterized by small irregular opacities, especially at the lung bases) and necrobiotic nodules (seen on radiographs as 1-3 cn. round shadows). Both of these are sometimes observed in seropositive patients without clinical rheumatoid arthritis. In asbestosis both types of lung lesion are seen, and circulating rheumatoid factor has now been demonstrated in about a quarter of these cases, associated with polyarthritis in four instances.
Large necrobiotic pulmonary nodules are probably very rare in asbestos workers but are well recognized in coal miners with and without rheumatoid arthritis (Caplan et al., 1962) . Micronodular opacities (0.3 to 1 cm. diameter) in coal miners are also associated with circulating rheumatoid factors, again in those with and without arthritis. Similar micronodular lesions have been described in asbestosis (Nice and Ostrolenk, 1968; Solomon, 1969) , and were seen in six of our cases-in three instances associated with circulating rheumatoid factor. Diffuse interstitial fibrosis (often with honeycombing) is also seen occasionally in coal miners' lungs with or without coal pneumoconiosis, again in association with circulating rheumatoid factor. Though there is no direct evidence to prove that this is more than a fortuitous association, the observation is of particular interest in the context of the foregoing discussion.
The (Holborow and Johnson, 1965) ; this is now being investigated. Alternatively, circulating autoantibodies may in some other way enhance tissue damage caused by asbestos dust. Another explanation for the increased prevalence of circulating antibodies is that, for some reason at present unknown those members of the general population with a genetic tendency to produce antiglobulin and antinuclear factors may react in an abnormal way to inhalation of asbestos or to the inflammatory response it provokes, and are therefore selected out into the group of exposed subjects developing lung changes. A further survey is now in progress to study the incidence of tissue antibodies in large numbers of asbestos workers with and without evidence of lung disease. A similar selection process has been suggested to account for the increased prevalence of rheumatoid factor in certain categories of coal miners' pneumoconiosis (Lindars and Davies, 1967) . If this theory proves correct then screening for circulating antinuclear and antiglobulin factors before acceptance into any industry with an asbestos hazard might form a basis for excluding from risk those with unusual susceptibility.
clummary: Sulphadimidine acetylation studies were un-")dertaken in 103 patients, 52 of whom had been classified as slow and 51 as rapid inactivators of isoniazid by a standard microbiological assay method. Each patient received sulphadimidine by mouth in a dose of 44 mg./kg. body weight, and free and total sulphadimidine were estimated in blood and urine collected at six hours. The findings suggest that patients may be classified as slow inactivators of isoniazid if the proportion of acetylated sulphadimidine (total minus free) is (a) less than 25% in blood or (b) less than 70% in urine. The sulphadimidine test is easy to perform and the result is available the same day; urine specimens for the test can be stored at room temperature for over a week without any loss of drug.
Introduction
Several investigators have shown that the rate of inactivation of isoniazid depends on the rate of its acetylation (Evans and White, 1964; Peters, Miller, and Brown, 1965) , and that individuals can be broadly classified as slow or rapid inactivators (Knight, Selin, and Harris, 1959; Evans, Manley, and McKusick, 1960; Jenne, 1960; Sunahara, Urano, and Ogawa, 1961) . Until recently the determination of the rate of inactivation had little practical value in the chemotherapy of pulmonary tuberculosis, since the rate was of little or no prognostic importance with daily regimens (Harris, 1959 (Harris, , 1961 Selkon et al., 1961; Schmidt, 1962; Scottish Thoracic Society, 1962; Tuberculosis Chemotherapy Centre, Madras, 1963) . With the advent of intermittent regimens, however, the determination of the isoniazid inactivation rate acquired much practical importance. For instance, a recent study from this centre showed that the response of rapid inactivators of isoniazid to once-weekly regimens of chemotherapy is substantially inferior to that of slow inactivators (Menon, 1968; Tuberculosis Chemotherapy Ventre, Madras, 1970) .
The rate of inactivation of isoniazid is usually determined by estimating the concentration of free isoniazid in the serum (by microbiological or chemical methods) at a specified time after a test dose of the drug. However, the need for collecting
